Reading : 372
Share :

The relevant article of the Notification on Health Practice, which allows SMA Type 2-3 patients to have access to the drug Spinraza, has been changed.


ARTICLE 1- In the Article 4.2.49.B of the Social Security Institution Health Implementation Notification published in the Official Gazette dated 24/3/2013 and numbered 28597,the following arrangements have been made.

  1. a) The second paragraph has been changed as follows.

“(2) The posology of“ Nusinersen Sodium ”is 4 loading doses on the 0th, 14th, 28th and 63rd days in SMA Type-2 or SMA Type-3 patients. Maintenance doses are also administered every 4 months. The costs are covered by the Institution in the event of that it is prescribed separately for each application by a pediatric neurology /neurology specialist with the "Drug Use Confirmation" that will be given by "Ministry of Health- Turkey Pharmaceuticals and Medical Devices Agency Evaluation Commission for the Use of Drugs For Personal Treatment" based on the single health board report for the first 4 doses and separate health report for each application in maintenance treatment.

  1. b) The fourth paragraph has been repealed.

ARTICLE 2 - The price of the drug named SPINRAZA 12 MG / 5 ML 1 VIAL with barcode number "1111111101517" in the "Overseas Drug Price List (ANNEX-4 / C)" attached to the same Notification has been changed as follows.

ARTICLE 3 -This Notification shall be effective on the date of publication.

ARTICLE 4 - The provisions of this Notification are executed by the President of the Social Security Institution.


Click here to access the page of the amendment in the Official Gazette.

Eskişehir Web Tasarım